Roche has officially announced the launch of AXELIOS 1, a next-generation sequencing platform built on proprietary SBX technology, promising same-day whole-genome sequencing with unprecedented speed and accuracy.
Merck KGaA has entered into a definitive agreement to acquire Bio-Techne for US$73 per share in cash, representing an enterprise value of US$11.3 billion to strengthen its global leadership in high-growth life sciences markets.
Eli Lilly and Company has announced the successful completion of its acquisition of Centessa Pharmaceuticals plc, integrating a clinical-stage portfolio of orexin receptor 2 agonists to address severe sleep-wake disorders.
AbbVie and Apogee Therapeutics have announced a definitive $10.9 billion acquisition agreement. The transaction enhances AbbVie’s global immunology portfolio by adding advanced assets like zumilokibart (APG777) for atopic dermatitis and APG273 for asthma.
Pharmaceutical titan AbbVie is in advanced discussions to purchase anti-inflammatory biotech developer Apogee Therapeutics for $10.9 billion in cash, marking its most significant bolt-on transaction since 2019.
Novo Nordisk A/S has confirmed an IT security breach involving unauthorized access to limited internal systems and data exfiltration. Core operations remain unaffected.
Danaher Corporation has finalized its acquisition of Masimo Corporation, establishing the pulse oximetry and patient monitoring provider as a stand-alone operating company within its Diagnostics segment.
Johnson & Johnson has announced a definitive agreement to acquire Firefly Bio, Inc. for $1 billion in cash to secure its novel Firelinkâ„¢ degrader antibody conjugate platform.
Gilead Sciences has commended the leadership of the South African Government and the Global Fund for accelerating early access to its long-acting HIV prevention medication, lenacapavir.
Novo Nordisk has expanded global access to obesity care by launching the once-daily Wegovy pill in the United Arab Emirates, offering a non-injectable alternative with a 17% mean weight loss and MACE risk reduction.
